Advertisement
Under the new agreement, Novo Nordisk is responsible for the developmentand commercialization of the product candidates. Novo Nordisk and Emispherehave collaborated since 2007 on early-stage pre-clinical research that haspreliminarily confirmed the utility of Emisphere's carriers to providebioavailable oral formulations of GLP-1 receptor agonists.
Advertisement
"This partnership with Novo Nordisk is important for Emisphere for severalreasons," said Michael V. Novinski, President and Chief Executive Officer ofEmisphere. "First, it couples Emisphere with Novo Nordisk, the worldwideleader in the field of diabetes research. Second, it places our technologywith a treatment for diabetes that we hope will be able to improve upon thehealthcare of millions of patients with this disease. Finally, it alsopositions our eligen(R) technology in such a way that helps to bringinnovative solutions to the pharmaceutical development arena."
"This is an encouraging agreement on a promising technology for oraladministration of proteins. It fits very well with Novo Nordisk's strategywithin diabetes research," said Peter Kurtzhals, Senior Vice President,Diabetes Research Unit.
Emisphere's broad-based drug delivery technology platform, known as theeligen(R) technology, uses proprietary, synthetic chemical compounds, known asEmisphere delivery agents, sometimes called carriers. Emisphere's eligen(R)technology makes it possible to deliver a therapeutic molecule withoutaltering its chemical form or biological integrity.
ABOUT EMISPHERE TECHNOLOGIES, INC.
Emisphere Technologies, Inc. is a biopharmaceutical company that focuseson a unique and improved delivery of therapeutic molecules and pharmaceuticalcompounds using its eligen(R) Technology. Some of these molecules or compoundscan only be given by injection; when combined with our technology; convenientoral versions may be safe, effective and provide significant advantages. Thebenefits of other compounds are limited due to poor bioavailability, slowon-set of action or variable absorption. In those cases, use of Emisphere'stechnology can improve the therapeutic effectiveness of the compounds. Theeligen(R) technology can be applied to the oral route of administration aswell other delivery pathways. The Web site is: www.emisphere.com.
ABOUT NOVO NORDISK.
Novo Nordisk is a healthcare company and a world leader in diabetes care.In addition, Novo Nordisk has a leading position within areas such ashaemostasis management, growth hormone therapy and hormone replacementtherapy. Novo Nordisk manufactures and markets pharmaceutical products andservices that make a significant difference to patients, the medicalprofession and society. With headquarters in Denmark, Novo Nordisk employsapproximately 26,300 employees in 80 countries, and markets its products in179 countries. Novo Nordisk's B shares are listed on the stock exchanges inCopenhagen and London. Its ADRs are listed on the New York Stock Exchangeunder the symbol NVO. For more information, visit www.novonordisk.com.
Safe Har
